Nvax had recently been approved or was in late stage trials for nanoflu- their seasonal influenza vaccine when they received BARDA funding- plus my understanding is that they also had some serious Washington influence- that part may just be rumor. Could it just as easily been us? Perhaps.. But chasing the COVID carrot can be a crazy ride as Nvax has seen- over 50% drop since February. I am here for all the other things Gnbt has like I was for nvax’s nanoflu. Hopefully those assets will be sufficient to get our IPO- and soon. But as I have said many times in the past. Eye on the ball- and the ball is the uplist and generating revenue from our core businesses. If the complete vaccine comes to fruition so much the better!!! But if I had to chose I like the basket with a lot of eggs in it.